You are here

H-Desmopressin Spray 25


Pharmacodynamics H-desmopressin spray is specifically targeted at the pathogenesis of diabetes insipidus, the main symptoms of which are excessive urine (polyuria) and its low density (hypoisostenuria). The reason for polyuria lies in the deficit of the antidiuretic nanopeptide neurohormone vasopressin, produced in the hypothalamus. This hormone regulates the osmolarity and osmotic pressure of liquids in the body, and also stimulates the reverse absorption (reabsorption) of water in the tubule system of renal nephrons.

The drug H-desmopressin spray contains a synthetic analogue of the endogenous hormone arginine-vasopressin, the active substance desmopressin acetate (DDAVP, 1-deamino-8-arginine vasopressin). Its structure was altered, which repeatedly increased vasopressor activity and effects on the V2-receptors of renal tubule cells.

H-desmopressin spray helps increase the permeability of the renal tubular membrane, which leads to increased water reabsorption and, consequently, to a decrease in the volume of excreted urine. In addition, the osmolar concentration of urine increases and the osmolarity of the blood plasma decreases, and this reduces the frequency of urination, including at night.


After the administration of 10-20 μg of spray, no more than 20% of the dose is absorbed into the nasal passages through the nasal mucosa. 20-30 minutes after the use of the drug, its active substance is found in the blood plasma; the maximum concentration is noted after 60 minutes. The duration of the therapeutic treatment is from 8 to 12 hours.

The H-desmopressin spray intake in the systemic blood stream does not exceed 3-5% in unchanged form. Through the BBB the active substance of the drug does not penetrate.

The average half-life is 2.5 hours. An insignificant amount of desmopressin undergoes biotransformation in the liver.


Contraindications for the use of H-desmopressin spray include: individual hypersensitivity to desmopressin; damage to the nasal mucosa; children up to 3 months; pathologically increased thirst (polydipsia); coronary insufficiency; mean and severe renal failure; chronic deficiency of sodium ions in blood plasma (hyponatremia); neurocrine disorder in the form of inadequate production of antidiuretic hormone vasopressin.

Last update: 21.12.2018
Found an error? Select it and press Ctrl + Enter.
You are reporting a typo in the following text:
Simply click the "Send typo report" button to complete the report. You can also include a comment.